Endocardium

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

Retrieved on: 
화요일, 10월 24, 2023
Fungal infection, Stroke, Phage therapy, Staphylococcus aureus, Incidence, National Agency for Food and Drug Administration and Control, Heart, Medication, Teaching hospital, Hope, Mortality, Endocarditis, Safety, ANSM, Infection, CEST, Pharmacokinetics, Endocardium, Clinical trial, S. aureus, Jean-Pierre du Teil, Bacteria, Blood, S, Therapy, Patient, Heart failure, CPP, Pharmaceutical industry

Endocarditis is an infection of the endocardium (inner lining of the heart) and valves, usually caused by bacteria.

Key Points: 
  • Endocarditis is an infection of the endocardium (inner lining of the heart) and valves, usually caused by bacteria.
  • The main cause of endocarditis infections, S. aureus, is responsible for around 30%1 of cases.
  • Pascal Birman, Chief Medical Officer of PHAXIAM Therapeutics, stated: "This phase 1 study was designed primarily to assess the safety and pharmacokinetics of our anti-S. aureus phages in the treatment of endocarditis infections.
  • The treatment of endocarditis infections caused by S. aureus using phage therapy could thus offer a major alternative and hope to many patients who have reached a therapeutic impasse.”

Left Atrial Appendage (LAA) Closure Device Market to Reach USD 8.2 Billion, Globally, by 2031 at 21% CAGR: Allied Market Research

Retrieved on: 
금요일, 9월 16, 2022
Infarction, Adoption, Incidence, Hospital, Bleeding, COVID-19, Bed, Growth, Stroke, Patient, SH, LAA, ICU, Atrial fibrillation, Endocardium, Research, Smoking, Awareness, Intensive care unit, CAGR, Medical device, Pharmaceutical industry

PORTLAND, Ore., Sept. 16, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Left Atrial Appendage (LAA) Closure Device Market by Product (Endocardial LAA Devices, Epicardial LAA Devices), by End Use (Hospitals, Ambulatory Surgery Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global left atrial appendage closure device industry generated $1.3 billion in 2021, and is estimated to reach $8.2 billion by 2031, witnessing a CAGR of 21.0% from 2022 to 2031.

Key Points: 
  • According to the report, the global left atrial appendage closure device industry generated $1.3 billion in 2021, and is estimated to reach $8.2 billion by 2031, witnessing a CAGR of 21.0% from 2022 to 2031.
  • Rise in number product approvals for atrial intervention, surge in atrial fibrillation, heart stroke cases, and hypertension-related diseases, and unhealthy lifestyle choices such as smoking drive the growth of the global left atrial appendage closure device market.
  • The Covid-19 pandemic made a considerable impact on the left atrial appendage closure devices market.
  • This is due to widespread acceptance of advanced left atrial appendage closure devices, rise in incidence of atrial fibrillation, and well-developed healthcare infrastructure.

CardioWise Joins the Lucem Health Innovation Collaborative as a Founding Member

Retrieved on: 
금요일, 6월 10, 2022
Caregiver, Squeezed states of light, Cardiovascular disease, CVD, Artificial intelligence, Artery, Software, AI, CEO, Algorithm, Endocardium, Digital, Ad Lucem, Physician, CT scan, Patient, CT, Adoption, Movement, Coronary artery disease, Radiation, General Catalyst, Muscle tissue, LV, Heart, Mayo Clinic, Data science, Baylor Research and Innovation Collaborative, Medical device, Medical imaging

FAYETTEVILLE, Ark., June 10, 2022 /PRNewswire-PRWeb/ -- CardioWise® and Lucem Health™ announced that CardioWise has become a founding member of the Lucem Health Innovation Collaborative, a partner program designed to help AI/ML innovation move to the forefront of healthcare. The collaborative launched by Mayo Clinic along with other investing partners will help digital health innovators create, deploy, and commercialize transformational solutions powered by artificial intelligence and machine learning models.

Key Points: 
  • FAYETTEVILLE, Ark., June 10, 2022 /PRNewswire-PRWeb/ -- CardioWise and Lucem Health announced that CardioWise has become a founding member of the Lucem Health Innovation Collaborative, a partner program designed to help AI/ML innovation move to the forefront of healthcare.
  • "AI has the potential to revolutionize how healthcare is delivered," said Sean Cassidy, CEO, Lucem Health.
  • Our Innovation Collaborative partners have a "solution first" mindset that considers all the requirements that must be in place for AI to be useful, trusted, and adopted."
  • Together, Lucem and CardioWise will provide caregivers with next-generation algorithms and data that allows physicians to make better, more informed decisions about their patients' care."

Left Atrial Appendage Closure Devices Market Revenue to Cross USD 2.5B by 2027: Global Market Insights Inc.

Retrieved on: 
월요일, 9월 13, 2021
Arrhythmia, Prevalence, Medicare, Medicare Payment Advisory Commission, First Nations in Ontario, Incidence, Stroke, Hospital, United Nations, LAA, CAGR, Atrial fibrillation, Kidney, Boston Scientific, Patient, USD, Mortality, Inflation, European Society of Aesthetic Surgery, Safety, Association, Ageing, ToC, Hypertension, Endocardium, Abbott Laboratories, European Society of Cardiology, GLOBE, Population, Johnson, Liquor, Pharmaceutical industry

SELBYVILLE, Del., Sept. 13, 2021 (GLOBE NEWSWIRE) -- According to the latest report, "Left Atrial Appendage (LAA) Closure Devices Market by Product (Endocardial LAA Devices, Epicardial LAA Devices), By Procedure (Percutaneous, Surgical), By End-use (Hospitals, Ambulatory Surgical Centers), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027", by Global Market Insights Inc., the market valuation of left atrial appendage closure devices will cross $2.5 billion by 2027.

Key Points: 
  • SELBYVILLE, Del., Sept. 13, 2021 (GLOBE NEWSWIRE) -- According to the latest report, "Left Atrial Appendage (LAA) Closure Devices Market by Product (Endocardial LAA Devices, Epicardial LAA Devices), By Procedure (Percutaneous, Surgical), By End-use (Hospitals, Ambulatory Surgical Centers), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027", by Global Market Insights Inc., the market valuation of left atrial appendage closure devices will cross $2.5 billion by 2027.
  • The epicardial left atrial appendage closure devices market was valued at around USD 87 million in 2020.
  • The surgical segment in the left atrial appendage closure devices market captured 18% of revenue share in 2020 and is expected to expand at a 31.4% growth rate through 2017.
  • China held a substantial revenue share in the Asia Pacific left atrial appendage closure devices market in 2020 and will reach over USD 225 million by 2027.

Occlutech's Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation for Heart Failure (HF)

Retrieved on: 
화요일, 1월 19, 2021
Anatomy, Branches of biology, Heart diseases, Heart failure, Endocardium, Heart, Cardiac muscle, Pericardium, Outline of cardiology

Heart failure (HF) is a serious condition characterized by the heart's inability to pump an adequate blood supply to the body.

Key Points: 
  • Heart failure (HF) is a serious condition characterized by the heart's inability to pump an adequate blood supply to the body.
  • HF may result from disorders of the pericardium, myocardium, endocardium, heart valves, great vessels, or specific metabolic abnormalities.
  • Reduced left atrial pressure has been shown to reduce heart failure symptoms and improve exercise tolerance.
  • "It is an important milestone for us to have received this second breakthrough designation for our AFR device."

Occlutech's Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation for Heart Failure (HF)

Retrieved on: 
화요일, 1월 19, 2021
Anatomy, Branches of biology, Heart diseases, Heart failure, Endocardium, Heart, Cardiac muscle, Pericardium, Outline of cardiology

Heart failure (HF) is a serious condition characterized by the heart's inability to pump an adequate blood supply to the body.

Key Points: 
  • Heart failure (HF) is a serious condition characterized by the heart's inability to pump an adequate blood supply to the body.
  • HF may result from disorders of the pericardium, myocardium, endocardium, heart valves, great vessels, or specific metabolic abnormalities.
  • Reduced left atrial pressure has been shown to reduce heart failure symptoms and improve exercise tolerance.
  • "It is an important milestone for us to have received this second breakthrough designation for our AFR device."

CardioWise™ Receives US FDA 510(k) Clearance for Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) Heart Function Analysis Software

Retrieved on: 
수요일, 1월 6, 2021
Anatomy, Branches of biology, CT scan, Multidimensional signal processing, Endocardium, Radiology, Cardiac muscle

SQuEEZ is an image analysis software application for cardiac Computer Tomography (CT) studies to assist cardiologists and radiologists in assessing function when producing a cardiac evaluation.

Key Points: 
  • SQuEEZ is an image analysis software application for cardiac Computer Tomography (CT) studies to assist cardiologists and radiologists in assessing function when producing a cardiac evaluation.
  • The software calculates a Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) value to highlight and color code motions of the heart wall.
  • CardioWise is commercializing patented, non-invasive Cardiac CT analysis software that produces a quantified 4D image model of the human heart, called Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ).
  • CardioWise heart analysis software combined with cardiac CT is a single diagnostic test that is able to provide quantitative analysis of the myocardium, arteries and valves with an unprecedented level of detail.